UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 23, 2016
|
ADMA BIOLOGICS, INC.
|
|
(Exact name of registrant as specified in its charter)
|
| |
|
|
|
Delaware
|
001-36728
|
56-2590442
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
| |
|
|
465 State Route 17 Ramsey, New Jersey
|
07446
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (201) 478-5552
| |
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 1.01 Entry into a Material Definitive Agreement.
Amended and Restated Plasma Supply Agreement
On March 23, 2016, ADMA Biologics, Inc. (the "Company") entered into an Amended and Restated Plasma Supply Agreement (the "A&R Supply Agreement") which amends and restates the Plasma Supply Agreement, dated June 22, 2012, as amended (the "Plasma Supply Agreement"), between the Company and Biotest Pharmaceuticals Corporation ("Biotest") for the purchase by Biotest of normal source plasma from the Company's plasma collection centers. The A&R Supply Agreement primarily incorporates prior amendments and updates the Plasma Supply Agreement to specifically provide for the Company's additional plasma center.
The foregoing description of the A&R Supply Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement, which the Company has filed as Exhibit 10.10 to its Annual Report on Form 10-K for the year ended December 31, 2016.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
March 29, 2016
|
ADMA Biologics, Inc.
|
| |
|
| |
|
| |
By:
|
/s/ Brian Lenz
|
| |
|
Name:
|
Brian Lenz
|
| |
|
Title:
|
Chief Financial Officer
|